Phio Pharmaceuticals Corp. has disclosed a notable stock acquisition by its Chairman, President, and CEO, Robert J. Bitterman. The acquisition of 25,000 shares at a price of $0.82 each reflects a strong vote of confidence in the company’s future prospects.

This acquisition is particularly significant as it comes at a time when the pharmaceutical preparations industry is navigating various challenges and opportunities. Bitterman's increased stake, now totaling 789,871 shares, may signal to investors and the market that he believes in the company’s potential growth and stability.

Background

Phio Pharmaceuticals Corp., incorporated in Delaware, operates within the pharmaceutical preparations sector, classified under SIC code 2834. The company trades on the Nasdaq under the ticker symbol PHIO. Recent filings indicate that Phio is a smaller reporting company, which may influence its strategic decisions and market interactions.

What the Filing Says

The recent filing, accession number 0001683168-26-008469, details Bitterman’s transaction on November 9, 2026. It states, "transaction code P" for purchase, indicating the acquisition of 25,000 shares. Following this transaction, Bitterman now owns 789,871 shares, which includes shares underlying unvested restricted stock units.

Impact

This acquisition may affect various stakeholders, including investors, employees, and competitors in the pharmaceutical preparations industry. Investors may view this move as a positive indicator of the company's future, potentially influencing their decisions regarding Phio's stock. Employees might feel reassured by the leadership's commitment, while competitors could see this as a sign of confidence that may impact their strategies.

What's Next

The filing does not say what happens next.